ARYZTA AG

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, UVRBY has a market cap of 249.8B. Regarding current trading prices, ARZTF is priced at $82.80, while UVRBY trades at $14.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas UVRBY's P/E ratio is 15.58. In terms of profitability, ARZTF's ROE is +0.22%, compared to UVRBY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to UVRBY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check UVRBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NSRGY has a market cap of 238.7B. Regarding current trading prices, ARZTF is priced at $82.80, while NSRGY trades at $92.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NSRGY's P/E ratio is 18.59. In terms of profitability, ARZTF's ROE is +0.22%, compared to NSRGY's ROE of +0.32%. Regarding short-term risk, ARZTF is more volatile compared to NSRGY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NSRGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NSRGF has a market cap of 236.8B. Regarding current trading prices, ARZTF is priced at $82.80, while NSRGF trades at $93.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NSRGF's P/E ratio is 18.80. In terms of profitability, ARZTF's ROE is +0.22%, compared to NSRGF's ROE of +0.32%. Regarding short-term risk, ARZTF is more volatile compared to NSRGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NSRGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GPDNF has a market cap of 56B. Regarding current trading prices, ARZTF is priced at $82.80, while GPDNF trades at $86.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GPDNF's P/E ratio is 26.11. In terms of profitability, ARZTF's ROE is +0.22%, compared to GPDNF's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to GPDNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GPDNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, DANOY has a market cap of 54.4B. Regarding current trading prices, ARZTF is priced at $82.80, while DANOY trades at $16.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas DANOY's P/E ratio is 25.55. In terms of profitability, ARZTF's ROE is +0.22%, compared to DANOY's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to DANOY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check DANOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, JBSAY has a market cap of 30.6B. Regarding current trading prices, ARZTF is priced at $82.80, while JBSAY trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas JBSAY's P/E ratio is 6.94. In terms of profitability, ARZTF's ROE is +0.22%, compared to JBSAY's ROE of +0.25%. Regarding short-term risk, ARZTF is more volatile compared to JBSAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check JBSAY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, AJINF has a market cap of 26.4B. Regarding current trading prices, ARZTF is priced at $82.80, while AJINF trades at $26.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas AJINF's P/E ratio is 112.25. In terms of profitability, ARZTF's ROE is +0.22%, compared to AJINF's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to AJINF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check AJINF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ASBFY has a market cap of 23.2B. Regarding current trading prices, ARZTF is priced at $82.80, while ASBFY trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ASBFY's P/E ratio is 13.18. In terms of profitability, ARZTF's ROE is +0.22%, compared to ASBFY's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to ASBFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ASBFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ASBFF has a market cap of 21.1B. Regarding current trading prices, ARZTF is priced at $82.80, while ASBFF trades at $29.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ASBFF's P/E ratio is 12.43. In terms of profitability, ARZTF's ROE is +0.22%, compared to ASBFF's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to ASBFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ASBFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, JDEPF has a market cap of 17.5B. Regarding current trading prices, ARZTF is priced at $82.80, while JDEPF trades at $36.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas JDEPF's P/E ratio is 25.22. In terms of profitability, ARZTF's ROE is +0.22%, compared to JDEPF's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to JDEPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check JDEPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, KRYAF has a market cap of 16.8B. Regarding current trading prices, ARZTF is priced at $82.80, while KRYAF trades at $103.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas KRYAF's P/E ratio is 21.31. In terms of profitability, ARZTF's ROE is +0.22%, compared to KRYAF's ROE of +0.11%. Regarding short-term risk, ARZTF is more volatile compared to KRYAF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check KRYAF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, KRYAY has a market cap of 15.9B. Regarding current trading prices, ARZTF is priced at $82.80, while KRYAY trades at $94.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas KRYAY's P/E ratio is 19.52. In terms of profitability, ARZTF's ROE is +0.22%, compared to KRYAY's ROE of +0.11%. Regarding short-term risk, ARZTF is more volatile compared to KRYAY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check KRYAY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, WHGRF has a market cap of 13.9B. Regarding current trading prices, ARZTF is priced at $82.80, while WHGRF trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas WHGRF's P/E ratio is 8.31. In terms of profitability, ARZTF's ROE is +0.22%, compared to WHGRF's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to WHGRF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check WHGRF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, AJINY has a market cap of 13.9B. Regarding current trading prices, ARZTF is priced at $82.80, while AJINY trades at $27.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas AJINY's P/E ratio is 113.17. In terms of profitability, ARZTF's ROE is +0.22%, compared to AJINY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to AJINY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check AJINY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, WHGLY has a market cap of 13.8B. Regarding current trading prices, ARZTF is priced at $82.80, while WHGLY trades at $21.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas WHGLY's P/E ratio is 8.52. In terms of profitability, ARZTF's ROE is +0.22%, compared to WHGLY's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to WHGLY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check WHGLY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, BMBOY has a market cap of 13.4B. Regarding current trading prices, ARZTF is priced at $82.80, while BMBOY trades at $12.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas BMBOY's P/E ratio is 21.75. In terms of profitability, ARZTF's ROE is +0.22%, compared to BMBOY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to BMBOY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check BMBOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GRBMF has a market cap of 13.3B. Regarding current trading prices, ARZTF is priced at $82.80, while GRBMF trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GRBMF's P/E ratio is 21.43. In terms of profitability, ARZTF's ROE is +0.22%, compared to GRBMF's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to GRBMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GRBMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ORKLY has a market cap of 11.2B. Regarding current trading prices, ARZTF is priced at $82.80, while ORKLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ORKLY's P/E ratio is 19.45. In terms of profitability, ARZTF's ROE is +0.22%, compared to ORKLY's ROE of +0.23%. Regarding short-term risk, ARZTF is more volatile compared to ORKLY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ORKLY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ORKLF has a market cap of 11B. Regarding current trading prices, ARZTF is priced at $82.80, while ORKLF trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ORKLF's P/E ratio is 18.97. In terms of profitability, ARZTF's ROE is +0.22%, compared to ORKLF's ROE of +0.23%. Regarding short-term risk, ARZTF is more volatile compared to ORKLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ORKLF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, BRZL has a market cap of 10.1B. Regarding current trading prices, ARZTF is priced at $82.80, while BRZL trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas BRZL's P/E ratio is N/A. In terms of profitability, ARZTF's ROE is +0.22%, compared to BRZL's ROE of +0.91%. Regarding short-term risk, ARZTF is less volatile compared to BRZL. This indicates potentially lower risk in terms of short-term price fluctuations for ARZTF.Check BRZL's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SAPIF has a market cap of 10.1B. Regarding current trading prices, ARZTF is priced at $82.80, while SAPIF trades at $24.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SAPIF's P/E ratio is -97.60. In terms of profitability, ARZTF's ROE is +0.22%, compared to SAPIF's ROE of -0.02%. Regarding short-term risk, ARZTF is more volatile compared to SAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SAPIF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CIADF has a market cap of 9.7B. Regarding current trading prices, ARZTF is priced at $82.80, while CIADF trades at $2.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CIADF's P/E ratio is 16.67. In terms of profitability, ARZTF's ROE is +0.22%, compared to CIADF's ROE of +0.00%. Regarding short-term risk, ARZTF is more volatile compared to CIADF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CIADF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, KIKOY has a market cap of 8.9B. Regarding current trading prices, ARZTF is priced at $82.80, while KIKOY trades at $18.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas KIKOY's P/E ratio is 21.31. In terms of profitability, ARZTF's ROE is +0.22%, compared to KIKOY's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to KIKOY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check KIKOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TTAZF has a market cap of 8.8B. Regarding current trading prices, ARZTF is priced at $82.80, while TTAZF trades at $7.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TTAZF's P/E ratio is 77.60. In terms of profitability, ARZTF's ROE is +0.22%, compared to TTAZF's ROE of N/A. Regarding short-term risk, ARZTF is more volatile compared to TTAZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TTAZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PIFFY has a market cap of 8.5B. Regarding current trading prices, ARZTF is priced at $82.80, while PIFFY trades at $14.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PIFFY's P/E ratio is 19.86. In terms of profitability, ARZTF's ROE is +0.22%, compared to PIFFY's ROE of +0.19%. Regarding short-term risk, ARZTF is more volatile compared to PIFFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PIFFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, WWNTF has a market cap of 8.4B. Regarding current trading prices, ARZTF is priced at $82.80, while WWNTF trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas WWNTF's P/E ratio is 14.20. In terms of profitability, ARZTF's ROE is +0.22%, compared to WWNTF's ROE of +0.18%. Regarding short-term risk, ARZTF is more volatile compared to WWNTF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check WWNTF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CIADY has a market cap of 8.3B. Regarding current trading prices, ARZTF is priced at $82.80, while CIADY trades at $21.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CIADY's P/E ratio is 526.63. In terms of profitability, ARZTF's ROE is +0.22%, compared to CIADY's ROE of +0.00%. Regarding short-term risk, ARZTF is more volatile compared to CIADY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CIADY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TCYMF has a market cap of 8.1B. Regarding current trading prices, ARZTF is priced at $82.80, while TCYMF trades at $1.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TCYMF's P/E ratio is 14.40. In terms of profitability, ARZTF's ROE is +0.22%, compared to TCYMF's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to TCYMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TCYMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TYCMY has a market cap of 8B. Regarding current trading prices, ARZTF is priced at $82.80, while TYCMY trades at $28.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TYCMY's P/E ratio is 13.99. In terms of profitability, ARZTF's ROE is +0.22%, compared to TYCMY's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to TYCMY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TYCMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, KIKOF has a market cap of 7.9B. Regarding current trading prices, ARZTF is priced at $82.80, while KIKOF trades at $8.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas KIKOF's P/E ratio is 19.18. In terms of profitability, ARZTF's ROE is +0.22%, compared to KIKOF's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to KIKOF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check KIKOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, LOTBY has a market cap of 7.8B. Regarding current trading prices, ARZTF is priced at $82.80, while LOTBY trades at $96.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas LOTBY's P/E ratio is 42.18. In terms of profitability, ARZTF's ROE is +0.22%, compared to LOTBY's ROE of +0.21%. Regarding short-term risk, ARZTF is more volatile compared to LOTBY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check LOTBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TATYY has a market cap of 7B. Regarding current trading prices, ARZTF is priced at $82.80, while TATYY trades at $29.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TATYY's P/E ratio is 47.89. In terms of profitability, ARZTF's ROE is +0.22%, compared to TATYY's ROE of +0.18%. Regarding short-term risk, ARZTF is more volatile compared to TATYY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TATYY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SDPNF has a market cap of 6.9B. Regarding current trading prices, ARZTF is priced at $82.80, while SDPNF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SDPNF's P/E ratio is 11.11. In terms of profitability, ARZTF's ROE is +0.22%, compared to SDPNF's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to SDPNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SDPNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TSUKY has a market cap of 6.9B. Regarding current trading prices, ARZTF is priced at $82.80, while TSUKY trades at $68.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TSUKY's P/E ratio is 16.18. In terms of profitability, ARZTF's ROE is +0.22%, compared to TSUKY's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to TSUKY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TSUKY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ARHUF has a market cap of 6.8B. Regarding current trading prices, ARZTF is priced at $82.80, while ARHUF trades at $26.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ARHUF's P/E ratio is 19.45. In terms of profitability, ARZTF's ROE is +0.22%, compared to ARHUF's ROE of +0.18%. Regarding short-term risk, ARZTF is more volatile compared to ARHUF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ARHUF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, DLLFF has a market cap of 6.5B. Regarding current trading prices, ARZTF is priced at $82.80, while DLLFF trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas DLLFF's P/E ratio is 14.00. In terms of profitability, ARZTF's ROE is +0.22%, compared to DLLFF's ROE of N/A. Regarding short-term risk, ARZTF is more volatile compared to DLLFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check DLLFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GCHOY has a market cap of 6.5B. Regarding current trading prices, ARZTF is priced at $82.80, while GCHOY trades at $10.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GCHOY's P/E ratio is 27.31. In terms of profitability, ARZTF's ROE is +0.22%, compared to GCHOY's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to GCHOY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GCHOY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GPAGF has a market cap of 6.4B. Regarding current trading prices, ARZTF is priced at $82.80, while GPAGF trades at $17.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GPAGF's P/E ratio is 11.53. In terms of profitability, ARZTF's ROE is +0.22%, compared to GPAGF's ROE of +0.27%. Regarding short-term risk, ARZTF is more volatile compared to GPAGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GPAGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TSUKF has a market cap of 6.2B. Regarding current trading prices, ARZTF is priced at $82.80, while TSUKF trades at $62.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TSUKF's P/E ratio is 15.97. In terms of profitability, ARZTF's ROE is +0.22%, compared to TSUKF's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to TSUKF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TSUKF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, MEJHF has a market cap of 5.5B. Regarding current trading prices, ARZTF is priced at $82.80, while MEJHF trades at $20.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas MEJHF's P/E ratio is 17.02. In terms of profitability, ARZTF's ROE is +0.22%, compared to MEJHF's ROE of +0.03%. Regarding short-term risk, ARZTF is more volatile compared to MEJHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check MEJHF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NFPDF has a market cap of 5.5B. Regarding current trading prices, ARZTF is priced at $82.80, while NFPDF trades at $18.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NFPDF's P/E ratio is 15.18. In terms of profitability, ARZTF's ROE is +0.22%, compared to NFPDF's ROE of +0.11%. Regarding short-term risk, ARZTF is more volatile compared to NFPDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NFPDF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, MEJHY has a market cap of 5.5B. Regarding current trading prices, ARZTF is priced at $82.80, while MEJHY trades at $10.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas MEJHY's P/E ratio is 15.97. In terms of profitability, ARZTF's ROE is +0.22%, compared to MEJHY's ROE of +0.07%. Regarding short-term risk, ARZTF is more volatile compared to MEJHY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check MEJHY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, EMLZF has a market cap of 5.4B. Regarding current trading prices, ARZTF is priced at $82.80, while EMLZF trades at $1,007.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas EMLZF's P/E ratio is 20.33. In terms of profitability, ARZTF's ROE is +0.22%, compared to EMLZF's ROE of +0.19%. Regarding short-term risk, ARZTF is more volatile compared to EMLZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check EMLZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CFEIY has a market cap of 5.4B. Regarding current trading prices, ARZTF is priced at $82.80, while CFEIY trades at $5.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CFEIY's P/E ratio is 10.95. In terms of profitability, ARZTF's ROE is +0.22%, compared to CFEIY's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to CFEIY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CFEIY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SMPFF has a market cap of 5.2B. Regarding current trading prices, ARZTF is priced at $82.80, while SMPFF trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SMPFF's P/E ratio is 13.38. In terms of profitability, ARZTF's ROE is +0.22%, compared to SMPFF's ROE of +0.24%. Regarding short-term risk, ARZTF is more volatile compared to SMPFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SMPFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CHFLF has a market cap of 4.9B. Regarding current trading prices, ARZTF is priced at $82.80, while CHFLF trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CHFLF's P/E ratio is 10.90. In terms of profitability, ARZTF's ROE is +0.22%, compared to CHFLF's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to CHFLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CHFLF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, IOIOF has a market cap of 4.7B. Regarding current trading prices, ARZTF is priced at $82.80, while IOIOF trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas IOIOF's P/E ratio is 12.64. In terms of profitability, ARZTF's ROE is +0.22%, compared to IOIOF's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to IOIOF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check IOIOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PIFMY has a market cap of 4.2B. Regarding current trading prices, ARZTF is priced at $82.80, while PIFMY trades at $25.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PIFMY's P/E ratio is 6.47. In terms of profitability, ARZTF's ROE is +0.22%, compared to PIFMY's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to PIFMY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PIFMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GLAPY has a market cap of 4.2B. Regarding current trading prices, ARZTF is priced at $82.80, while GLAPY trades at $81.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GLAPY's P/E ratio is 34.88. In terms of profitability, ARZTF's ROE is +0.22%, compared to GLAPY's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to GLAPY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GLAPY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NSLYF has a market cap of 4.2B. Regarding current trading prices, ARZTF is priced at $82.80, while NSLYF trades at $17.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NSLYF's P/E ratio is 44.87. In terms of profitability, ARZTF's ROE is +0.22%, compared to NSLYF's ROE of +0.70%. Regarding short-term risk, ARZTF is more volatile compared to NSLYF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NSLYF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GLAPF has a market cap of 4.2B. Regarding current trading prices, ARZTF is priced at $82.80, while GLAPF trades at $16.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GLAPF's P/E ratio is 35.60. In terms of profitability, ARZTF's ROE is +0.22%, compared to GLAPF's ROE of +0.11%. Regarding short-term risk, ARZTF is more volatile compared to GLAPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GLAPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PIFMF has a market cap of 4.1B. Regarding current trading prices, ARZTF is priced at $82.80, while PIFMF trades at $0.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PIFMF's P/E ratio is 7.83. In terms of profitability, ARZTF's ROE is +0.22%, compared to PIFMF's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to PIFMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PIFMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, ACOPF has a market cap of 4.1B. Regarding current trading prices, ARZTF is priced at $82.80, while ACOPF trades at $5.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas ACOPF's P/E ratio is 35.34. In terms of profitability, ARZTF's ROE is +0.22%, compared to ACOPF's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to ACOPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check ACOPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, MRRTY has a market cap of 3.6B. Regarding current trading prices, ARZTF is priced at $82.80, while MRRTY trades at $4.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas MRRTY's P/E ratio is 14.33. In terms of profitability, ARZTF's ROE is +0.22%, compared to MRRTY's ROE of +0.68%. Regarding short-term risk, ARZTF is more volatile compared to MRRTY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check MRRTY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, YMZBY has a market cap of 3.6B. Regarding current trading prices, ARZTF is priced at $82.80, while YMZBY trades at $180.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas YMZBY's P/E ratio is 14.04. In terms of profitability, ARZTF's ROE is +0.22%, compared to YMZBY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to YMZBY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check YMZBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FPAFF has a market cap of 3.5B. Regarding current trading prices, ARZTF is priced at $82.80, while FPAFF trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FPAFF's P/E ratio is 5.93. In terms of profitability, ARZTF's ROE is +0.22%, compared to FPAFF's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to FPAFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FPAFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NIPMY has a market cap of 3.5B. Regarding current trading prices, ARZTF is priced at $82.80, while NIPMY trades at $17.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NIPMY's P/E ratio is 18.68. In terms of profitability, ARZTF's ROE is +0.22%, compared to NIPMY's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to NIPMY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NIPMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FPAFY has a market cap of 3.5B. Regarding current trading prices, ARZTF is priced at $82.80, while FPAFY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FPAFY's P/E ratio is 5.77. In terms of profitability, ARZTF's ROE is +0.22%, compared to FPAFY's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to FPAFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FPAFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CRWKF has a market cap of 3.4B. Regarding current trading prices, ARZTF is priced at $82.80, while CRWKF trades at $63.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CRWKF's P/E ratio is 23.79. In terms of profitability, ARZTF's ROE is +0.22%, compared to CRWKF's ROE of +0.14%. Regarding short-term risk, ARZTF is more volatile compared to CRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CRWKF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NSFMF has a market cap of 3.3B. Regarding current trading prices, ARZTF is priced at $82.80, while NSFMF trades at $11.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NSFMF's P/E ratio is 14.20. In terms of profitability, ARZTF's ROE is +0.22%, compared to NSFMF's ROE of +0.07%. Regarding short-term risk, ARZTF is more volatile compared to NSFMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NSFMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NHFOF has a market cap of 3.3B. Regarding current trading prices, ARZTF is priced at $82.80, while NHFOF trades at $33.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NHFOF's P/E ratio is 18.44. In terms of profitability, ARZTF's ROE is +0.22%, compared to NHFOF's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to NHFOF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NHFOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, UVRBF has a market cap of 3.2B. Regarding current trading prices, ARZTF is priced at $82.80, while UVRBF trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas UVRBF's P/E ratio is 16.67. In terms of profitability, ARZTF's ROE is +0.22%, compared to UVRBF's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to UVRBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check UVRBF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, MLFNF has a market cap of 3.2B. Regarding current trading prices, ARZTF is priced at $82.80, while MLFNF trades at $25.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas MLFNF's P/E ratio is 24.64. In terms of profitability, ARZTF's ROE is +0.22%, compared to MLFNF's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to MLFNF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check MLFNF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PRBZF has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $82.80, while PRBZF trades at $69.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PRBZF's P/E ratio is 46.02. In terms of profitability, ARZTF's ROE is +0.22%, compared to PRBZF's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to PRBZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PRBZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TATYF has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $82.80, while TATYF trades at $6.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TATYF's P/E ratio is 43.44. In terms of profitability, ARZTF's ROE is +0.22%, compared to TATYF's ROE of +0.18%. Regarding short-term risk, ARZTF is more volatile compared to TATYF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TATYF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NCHEY has a market cap of 3.1B. Regarding current trading prices, ARZTF is priced at $82.80, while NCHEY trades at $12.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NCHEY's P/E ratio is 18.06. In terms of profitability, ARZTF's ROE is +0.22%, compared to NCHEY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to NCHEY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NCHEY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CBCFF has a market cap of 2.9B. Regarding current trading prices, ARZTF is priced at $82.80, while CBCFF trades at $23.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CBCFF's P/E ratio is 21.90. In terms of profitability, ARZTF's ROE is +0.22%, compared to CBCFF's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to CBCFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CBCFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, LYSFF has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $82.80, while LYSFF trades at $4.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas LYSFF's P/E ratio is 22.62. In terms of profitability, ARZTF's ROE is +0.22%, compared to LYSFF's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to LYSFF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check LYSFF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, LYSFY has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $82.80, while LYSFY trades at $9.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas LYSFY's P/E ratio is 21.86. In terms of profitability, ARZTF's ROE is +0.22%, compared to LYSFY's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to LYSFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check LYSFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, EBRPY has a market cap of 2.8B. Regarding current trading prices, ARZTF is priced at $82.80, while EBRPY trades at $17.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas EBRPY's P/E ratio is 20.34. In terms of profitability, ARZTF's ROE is +0.22%, compared to EBRPY's ROE of +0.06%. Regarding short-term risk, ARZTF is more volatile compared to EBRPY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check EBRPY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, EBRPF has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $82.80, while EBRPF trades at $17.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas EBRPF's P/E ratio is 15.72. In terms of profitability, ARZTF's ROE is +0.22%, compared to EBRPF's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to EBRPF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check EBRPF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TBLMF has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $82.80, while TBLMF trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TBLMF's P/E ratio is 12.77. In terms of profitability, ARZTF's ROE is +0.22%, compared to TBLMF's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to TBLMF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TBLMF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SUEZF has a market cap of 2.7B. Regarding current trading prices, ARZTF is priced at $82.80, while SUEZF trades at $13.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SUEZF's P/E ratio is -10.32. In terms of profitability, ARZTF's ROE is +0.22%, compared to SUEZF's ROE of -0.06%. Regarding short-term risk, ARZTF is more volatile compared to SUEZF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SUEZF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SUEZY has a market cap of 2.4B. Regarding current trading prices, ARZTF is priced at $82.80, while SUEZY trades at $5.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SUEZY's P/E ratio is -9.37. In terms of profitability, ARZTF's ROE is +0.22%, compared to SUEZY's ROE of -0.06%. Regarding short-term risk, ARZTF is more volatile compared to SUEZY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SUEZY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PFODF has a market cap of 2.4B. Regarding current trading prices, ARZTF is priced at $82.80, while PFODF trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PFODF's P/E ratio is 14.47. In terms of profitability, ARZTF's ROE is +0.22%, compared to PFODF's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to PFODF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PFODF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, CLBEY has a market cap of 2.3B. Regarding current trading prices, ARZTF is priced at $82.80, while CLBEY trades at $4.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas CLBEY's P/E ratio is 16.50. In terms of profitability, ARZTF's ROE is +0.22%, compared to CLBEY's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to CLBEY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check CLBEY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, PRRFY has a market cap of 2.3B. Regarding current trading prices, ARZTF is priced at $82.80, while PRRFY trades at $13.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas PRRFY's P/E ratio is 13.72. In terms of profitability, ARZTF's ROE is +0.22%, compared to PRRFY's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to PRRFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check PRRFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, SGLJF has a market cap of 2.2B. Regarding current trading prices, ARZTF is priced at $82.80, while SGLJF trades at $15.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas SGLJF's P/E ratio is 20.05. In terms of profitability, ARZTF's ROE is +0.22%, compared to SGLJF's ROE of +0.21%. Regarding short-term risk, ARZTF is more volatile compared to SGLJF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check SGLJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GRPBF has a market cap of 2.1B. Regarding current trading prices, ARZTF is priced at $82.80, while GRPBF trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GRPBF's P/E ratio is N/A. In terms of profitability, ARZTF's ROE is +0.22%, compared to GRPBF's ROE of N/A. Regarding short-term risk, ARZTF is more volatile compared to GRPBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GRPBF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FTROF has a market cap of 1.9B. Regarding current trading prices, ARZTF is priced at $82.80, while FTROF trades at $1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FTROF's P/E ratio is 7.62. In terms of profitability, ARZTF's ROE is +0.22%, compared to FTROF's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to FTROF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FTROF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, HOFJF has a market cap of 1.8B. Regarding current trading prices, ARZTF is priced at $82.80, while HOFJF trades at $19.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas HOFJF's P/E ratio is 23.90. In terms of profitability, ARZTF's ROE is +0.22%, compared to HOFJF's ROE of +0.04%. Regarding short-term risk, ARZTF is more volatile compared to HOFJF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check HOFJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TBLMY has a market cap of 1.7B. Regarding current trading prices, ARZTF is priced at $82.80, while TBLMY trades at $10.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TBLMY's P/E ratio is 12.02. In terms of profitability, ARZTF's ROE is +0.22%, compared to TBLMY's ROE of +0.17%. Regarding short-term risk, ARZTF is more volatile compared to TBLMY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TBLMY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FSRCY has a market cap of 1.7B. Regarding current trading prices, ARZTF is priced at $82.80, while FSRCY trades at $109.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FSRCY's P/E ratio is 9.57. In terms of profitability, ARZTF's ROE is +0.22%, compared to FSRCY's ROE of +0.08%. Regarding short-term risk, ARZTF is more volatile compared to FSRCY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FSRCY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, YNNHF has a market cap of 1.6B. Regarding current trading prices, ARZTF is priced at $82.80, while YNNHF trades at $1.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas YNNHF's P/E ratio is 15.45. In terms of profitability, ARZTF's ROE is +0.22%, compared to YNNHF's ROE of +0.16%. Regarding short-term risk, ARZTF is more volatile compared to YNNHF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check YNNHF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, AVSFY has a market cap of 1.6B. Regarding current trading prices, ARZTF is priced at $82.80, while AVSFY trades at $24.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas AVSFY's P/E ratio is 12.24. In terms of profitability, ARZTF's ROE is +0.22%, compared to AVSFY's ROE of +0.41%. Regarding short-term risk, ARZTF is more volatile compared to AVSFY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check AVSFY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GNCGY has a market cap of 1.5B. Regarding current trading prices, ARZTF is priced at $82.80, while GNCGY trades at $13.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GNCGY's P/E ratio is 0.26. In terms of profitability, ARZTF's ROE is +0.22%, compared to GNCGY's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to GNCGY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GNCGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TUFUF has a market cap of 1.5B. Regarding current trading prices, ARZTF is priced at $82.80, while TUFUF trades at $0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TUFUF's P/E ratio is 12.92. In terms of profitability, ARZTF's ROE is +0.22%, compared to TUFUF's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to TUFUF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TUFUF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GNCGF has a market cap of 1.5B. Regarding current trading prices, ARZTF is priced at $82.80, while GNCGF trades at $3.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GNCGF's P/E ratio is 0.26. In terms of profitability, ARZTF's ROE is +0.22%, compared to GNCGF's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to GNCGF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GNCGF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FNEVF has a market cap of 1.4B. Regarding current trading prices, ARZTF is priced at $82.80, while FNEVF trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FNEVF's P/E ratio is 12.16. In terms of profitability, ARZTF's ROE is +0.22%, compared to FNEVF's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to FNEVF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FNEVF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, HLFGY has a market cap of 1.4B. Regarding current trading prices, ARZTF is priced at $82.80, while HLFGY trades at $15.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas HLFGY's P/E ratio is 24.16. In terms of profitability, ARZTF's ROE is +0.22%, compared to HLFGY's ROE of +0.13%. Regarding short-term risk, ARZTF is more volatile compared to HLFGY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check HLFGY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, NISUY has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $82.80, while NISUY trades at $42.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas NISUY's P/E ratio is 10.62. In terms of profitability, ARZTF's ROE is +0.22%, compared to NISUY's ROE of +0.09%. Regarding short-term risk, ARZTF is more volatile compared to NISUY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check NISUY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, FNEVY has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $82.80, while FNEVY trades at $4.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas FNEVY's P/E ratio is 11.33. In terms of profitability, ARZTF's ROE is +0.22%, compared to FNEVY's ROE of +0.05%. Regarding short-term risk, ARZTF is more volatile compared to FNEVY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check FNEVY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GUZOF has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $82.80, while GUZOF trades at $3.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GUZOF's P/E ratio is 15.75. In terms of profitability, ARZTF's ROE is +0.22%, compared to GUZOF's ROE of +0.18%. Regarding short-term risk, ARZTF is more volatile compared to GUZOF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GUZOF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, VTSYF has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $82.80, while VTSYF trades at $1.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas VTSYF's P/E ratio is 39.33. In terms of profitability, ARZTF's ROE is +0.22%, compared to VTSYF's ROE of +0.04%. Regarding short-term risk, ARZTF is more volatile compared to VTSYF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check VTSYF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, TUFBY has a market cap of 1.3B. Regarding current trading prices, ARZTF is priced at $82.80, while TUFBY trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas TUFBY's P/E ratio is 8.70. In terms of profitability, ARZTF's ROE is +0.22%, compared to TUFBY's ROE of +0.10%. Regarding short-term risk, ARZTF is more volatile compared to TUFBY. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check TUFBY's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, AKEJF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $82.80, while AKEJF trades at $35.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas AKEJF's P/E ratio is 28.55. In terms of profitability, ARZTF's ROE is +0.22%, compared to AKEJF's ROE of +0.07%. Regarding short-term risk, ARZTF is more volatile compared to AKEJF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check AKEJF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, BTSDF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $82.80, while BTSDF trades at $1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas BTSDF's P/E ratio is -171.00. In terms of profitability, ARZTF's ROE is +0.22%, compared to BTSDF's ROE of -0.01%. Regarding short-term risk, ARZTF is more volatile compared to BTSDF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check BTSDF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, JWLLF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $82.80, while JWLLF trades at $26.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas JWLLF's P/E ratio is 27.10. In terms of profitability, ARZTF's ROE is +0.22%, compared to JWLLF's ROE of +0.12%. Regarding short-term risk, ARZTF is more volatile compared to JWLLF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check JWLLF's competition here

ARZTF plays a significant role within the Consumer Defensive sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ARZTF stands at 2.5B. In comparison, GBFBF has a market cap of 1.1B. Regarding current trading prices, ARZTF is priced at $82.80, while GBFBF trades at $2.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ARZTF currently has a P/E ratio of 690.00, whereas GBFBF's P/E ratio is 12.38. In terms of profitability, ARZTF's ROE is +0.22%, compared to GBFBF's ROE of N/A. Regarding short-term risk, ARZTF is more volatile compared to GBFBF. This indicates potentially higher risk in terms of short-term price fluctuations for ARZTF.Check GBFBF's competition here